Related Experiment Video
Updated: Jul 18, 2026

The Intra-Aortic Balloon Pump
Published on: February 5, 2021
The benefits of aggressive BP control in patients with CAD
Insights
It is time to intensify blood pressure (BP) control. New research indicates current national guidelines are insufficient for patients with cardiac disease, advocating for lower BP targets in treatment strategies.
Area of Science:
- Cardiology
- Hypertension Management
Background:
- Current blood pressure (BP) guidelines may not be aggressive enough for patients with existing cardiac conditions.
- Mounting evidence suggests a need for more stringent BP targets.
Purpose of the Study:
- To evaluate the adequacy of current national guidelines for BP control in patients with cardiac disease.
- To determine if lower BP targets are warranted for this patient population.
Main Methods:
- Review of recent research and clinical evidence regarding BP control targets.
- Analysis of data supporting more aggressive treatment strategies.
Main Results:
- Existing research suggests current BP targets are insufficient for patients with cardiac disease.
- Investigators find a compelling case for treating to lower BP targets.
Conclusions:
- Clinicians should consider more aggressive BP control measures for patients with cardiac disease.
- Current guidelines may need revision to incorporate lower BP targets for improved patient outcomes.
Abstract:
Is it time to get more aggressive with BP control? Evidence is mounting that the answer to that question is definitely yes. In fact, new research suggests that national guidelines simply don't go far enough with their recommended BP targets for patients who already have cardiac disease. More evidence would be nice, but investigators maintain there is already a compelling case for clinicians to treat to lower targets.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease I: Introduction
Heart Failure Drugs: β-Blockers
Hypertension IV: Drug Therapy and Lifestyle Modifications